Kivo reports that over half of new FDA-approved drugs are now for rare diseases, thanks to the Orphan Drug Act of 1983, which incentivized their development.
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you are a current print subscriber, you can set up a free website account by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
